Pharming Group N.V. ADS, each representing 10 ordinary shares
PHARPharming Group N.V. ADS is a biopharmaceutical company specializing in the development of innovative therapies for rare, unmet medical needs. The company focuses on producing recombinant protein therapies, including treatments for genetically defined diseases and conditions involving enzyme deficiencies. Pharming is known for its flagship product, Rapyda, used in the treatment of hereditary angioedema. The company's operations are centered around developing and commercializing biologic medicines for patients worldwide.
Company News
Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of global finance leadership experience in life sciences, previously serving as CFO at Schoeller Allibert, Zentiva, and holding senior roles at Gilead Sciences.
Pharming Group N.V., a global biopharmaceutical company, announces that its management team will participate in the 37th Annual Roth Conference in March 2025, where they will hold a fireside chat and be available for one-on-one meetings.
Pharming Group N.V., a global biopharmaceutical company, announces that its management team will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025.
Pharming Group N.V. announced a recommended public cash offer to acquire all outstanding shares of Abliva AB, a biotechnology company focused on developing treatments for mitochondrial diseases. Abliva's lead product, KL1333, is currently in a pivotal clinical trial and has shown positive results in a proof-of-concept study.
Pharming Group N.V., a global biopharmaceutical company, announces that its CEO will present at the Jefferies London Healthcare Conference 2024 on November 20, 2024.
